Alaunos Therapeutics, Inc. (TCRT)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Revenue | - | 2 | ||
| Research and development | 185 | 347 | ||
| General and administrative | 854 | 747 | ||
| Total operating expenses | 1,039 | 1,094 | ||
| Loss from operations | -1,039 | -1,092 | ||
| Other income, net | 19 | 19 | ||
| Change in fair value of warrant liability | 31 | - | ||
| Other income (expense), net | -12 | 19 | ||
| Net loss | -1,051 | -1,073 | ||
| Earnings per share, basic, total | -0.63 | -0.67 | ||
| Earnings per share, diluted, total | -0.63 | -0.67 | ||
| Weighted average number of shares outstanding, basic, total | 1,676,345 | 1,601,252 | ||
| Weighted average number of shares outstanding, diluted, total | 1,676,345 | 1,601,252 | ||